SUtoChildT1D: Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes

Sponsor

Haukeland University Hospital (Other)

Overall Status

Unknown status

CT.gov ID

NCT04239586

Collaborator

(none)

Enrollment

Location

Arm

59.4

Anticipated Duration (Months)

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to switch from insulin to oral sulfonylurea in patients with apparent type 1 diabetes or maturity onset diabetes in the young that are insulin treated. The molecular cause will be DNA variants in the HNF1A, HNF4A, or HNF1B genes that are of unknown significance (VUS, class 3) or known to be pathogenic (class 4 and 5).

Condition or Disease	Intervention/Treatment	Phase
Maturity-Onset Diabetes of the Young, Type 3 Maturity Onset Diabetes of the Young, Type 1 Childhood Diabetes Mellitus Insulin-dependent Diabetes Mellitus	Drug: Sulfonylurea	Phase 4

Detailed Description

Maturity onset diabetes in the young (MODY) is characterised by monogenic diabetes due to beta-cell dysfunction, with typical onset of diabetes before age of 25 years. There are 14 known forms of MODY, ranging from rather common to extremely rare.

About 1% of patients in the Norwegian Childhood Diabetes registry may have disease causing MODY mutations, according to a study recently published by the investigator's group and others.

MODY associated mutations in the transcription factors HNF1A, HNF4A, and HNF1B leads to activation of the potassium channel causing depolarisation of the beta-cell membrane, which is crucial for excretion of insulin. By treating patients with HNF1A-MODY, HNF4A-MODY, and HNF1B-MODY with sulfonylurea class of drugs, these channels will close, causing depolarisation of the beta-cell membrane, and release of insulin. Hence, these patients can often stop insulin treatment when they are treated with sulfonylurea class drugs.

Due to high throughput sequencing, a number of rare variants in these genes have been discovered. In many cases, bioinformatic tools are not sufficient to correctly classify these variants. In the present study, we intend to identify rare variants in the HNF1A, HNF4A, and HNF1B genes in patients with insulin dependent diabetes identified through the Norwegian Childhood Diabetes registry or the Norwegian MODY Registry with possibly disease causing HNF1A, HNF4A, or HNF1B mutations with sulfonylurea to see if they can reduce or even stop insulin treatment, and regulate their diabetes with sulfonylurea only. All variants will be investigated by bioinformatics tools as well as functional assays (tests for DNA-binding, transcriptional activation, nuclear localisation, protein expression). Primary endpoints are efficacy of sulfonylurea treatment measured by insulin requirement or not and level of HbA1c. Secondary endpoints are tolerance of sulfonylurea and effect on insulin secretion by oral and intravenous glucose tolerance tests. Bioinformatics and functional characterisation will be compared with success to reach primary endpoints.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

Switching insulin-treated diabetes patients with possibly disease causing mutations in HNF1A, HNF4A, or HNF1B to treatment with sulfonylurea.Switching insulin-treated diabetes patients with possibly disease causing mutations in HNF1A, HNF4A, or HNF1B to treatment with sulfonylurea.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Switching From Insulin to Sulfonylurea in Childhood and Adult Diabetes Due to Variants in the HNF1A, HNF4A, or HNF1B Genes

Actual Study Start Date :

Apr 18, 2017

Anticipated Primary Completion Date :

Apr 1, 2022

Anticipated Study Completion Date :

Apr 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Sulfonylurea treatment group Increasing doses of sulfonylurea class of drug to see whether insulin treatment can be reduced in dose or stopped.	Drug: Sulfonylurea Starting treatment with sulfonylurea class of drug Other Names: Glibenclamide Glipizide Glimerepiride

Arm

Intervention/Treatment

Experimental: Sulfonylurea treatment group

Increasing doses of sulfonylurea class of drug to see whether insulin treatment can be reduced in dose or stopped.

Drug: Sulfonylurea

Starting treatment with sulfonylurea class of drug

Other Names:

Glibenclamide

Glipizide

Glimerepiride

Outcome Measures

Primary Outcome Measures

Effect of sulfonylurea treatment on insulin requirement measured in units insulin per kg per day [5 years]
Effect of sulfonylurea treatment on insulin requirement measured in units insulin per kg bodyweight per day, recorded at intervals of 3-6 months after exposure to sulfonylurea compared to before initiation of sulfonylurea
Metabolic control of diabetes measured by HbA1c in mmol/mol [5 years]
Metabolic control of diabetes measured by HbA1c in mmol/mol, recorded at intervals of 3-6 months after exposure to sulfonylurea compared to before initiation of sulfonylurea

Secondary Outcome Measures

Level of sulfonylurea dose in mg per kg per day [5 years]
Level of sulfonylurea dose in mg per kg body weight per day, recorded at intervals of 3-6 months after exposure to sulfonylurea compared to before initiation of sulfonylurea
Prevalence of side effects of sulfonylurea [5 years]
Recording potential side effects of sulfonylurea, such as nausea, change in body weight, episodes of severe hypoglycemia, discolouration of teeth, diarrhoea, cardiovascular events, recorded at intervals of 3-6 months after exposure to sulfonylurea compared to before initiation of sulfonylurea
Effect on endogenous insulin secretion assessed by intravenous glucose tolerance tests [5 years]
Maximum increment of serum insulin in nmol/L and serum c-peptide in pmol/L at intravenous glucose tolerance tests, recorded at intervals of 6-12 months after exposure to sulfonylurea compared to before initiation of sulfonylurea
Effect on secretion of incretin hormones, assessed by oral glucose tolerance tests [5 years]
Maximum increment of serum insulin in nmol/L, serum c-peptide in pmol/L and incretins (GIP in pmol/L and GLP-1 in pmol/L) at oral glucose tolerance tests and in comparison with intravenous gluclose tolerance tests, recorded at intervals of 6-12 months after exposure to sulfonylurea compared to before initiation of sulfonylurea

Eligibility Criteria

Criteria

Ages Eligible for Study:

2 Years to 95 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diabetes and DNA sequence variant of unknown significance (VUS, class 3) or pathogenic (class 4, and 5) in the HNF1A, HNF4A, or HNF1B genes
On insulin treatment
Willing and able to provide informed consent (parents if younger than 16 years of age)

Exclusion Criteria:

Known anaphylactic response to sulfonylurea
Diabetes and DNA sequence variant in the HNF1A, HNF4A, or HNF1B genes that are known to be non-pathogenic (class 1-2)
Not willing or able to provide informed consent (parents if younger than 16 years of age)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Department of Pediatrics and Adolescents, Haukeland University Hospital, and Department of Clinical Science, Faculty of Medicine, University of Bergen	Bergen		Norway	NO-5021